Inferior medicines pose a major health risk

CDC.gov

  • Title:

    Phake: The Deadly World of Falsified and Substandard Medicines
  • Format:

    Paperback
  • Paperback Price:

    32.50
  • Paperback ISBN:

    978-0844772332
  • 486 Paperback pages
  • Format:

    HardCover
  • Hardcover ISBN:

    978-0-8447-7232-5
  • Buy the Book

Article Highlights

  • A significant proportion of drugs for malaria, TB and other deadly infections fail basic quality tests.

    Tweet This

  • Up to 15% of all drugs tested in African cities and 7% in Indian cities failed basic quality testing.

    Tweet This

  • 8.8 million people contracted TB in 2010 and at least 240 million people contracted malaria.

    Tweet This

  • A small but significant number of poor quality drugs found in Bates’ study had been quality-assured by the WHO.

    Tweet This

  • International pressure must be placed on Beijing & New Delhi to put their regulatory houses in order to monitor drug quality

    Tweet This

Global health agencies and western donors have made great efforts in recent years to subsidise and improve the supply of medicines for diseases affecting the world’s poorest people, particularly malaria, tuberculosis (TB) and other deadly infections.

It is, therefore, a serious cause for concern that a significant proportion of drugs for these diseases fail basic quality tests, potentially undermining these efforts and posing a grave threat to public health.

This week, my team of researchers publishes one of the world’s biggest studies into drug quality. Over the past four years, we purchased 2,652 samples of antimalarials, antibiotics and TB drugs from pharmacies in 19 cities across 17 developing and middle-income countries. The results are alarming: up to 15% of all drugs tested in African cities and 7% in Indian cities failed basic quality testing. A more detailed study of malaria drugs also just released found up to 40% of those bought in the two largest west African cities have insufficient active ingredient.

If a drug used to treat these diseases is not made to the highest standards, this means the sick patient is unlikely to recover and it increases the chance of malaria parasites or TB bacteria developing resistance to the treatment. This has the potential to render entire classes of medicines useless, making malaria or TB untreatable with currently available medicines. Given that 8,8-million people contracted TB in 2010, and at least 240-million malaria, the public health consequences are unthinkable.

Some of the substandard drugs we identified were most likely counterfeits.

But many more were made by local African, Indian or Chinese companies, but without the proper oversight of a competent government drug regulatory authority. Up to 25% of such drugs manufactured in Africa, 16% of those made in China and 4% of Indian drugs failed our testing, compared with 1,7% of those made in the European Union and the US.

More disturbingly, a small but significant number of poor-quality drugs we found had been quality-assured by the World Health Organisation (WHO), which has the responsibility for ensuring medicine standards in developing countries. While drugs approved by the WHO are generally high quality, there appears to be a problem with such products, especially antimalarials, manufactured in China. Nearly 18% of the WHO-approved Chinese products we tested did not reach required standards, contrasting with a still worrying 2,4% failure rate of Indian-made WHO-approved products.

There are several reasons this may be happening. The most acute problem is with artemisinin combination therapies, a modern class of malaria drug.

One explanation is that recent global shortages of artemisinin (the main natural ingredient in the drug, derived from the sweet wormwood plant) have led to supply problems, which has resulted in many companies being forced to cut corners in order to deliver their medicines to agreed timetables. Another explanation is more sinister. It may well be that certain Chinese (and to a lesser extent Indian) drug manufacturers are boosting profits by cutting corners in the manufacturing process of drugs they supply to Africa. As the drug regulatory failures in India and China are well known, this is not so difficult for unscrupulous manufacturers to get away with.

In April, the Indian drug regulator was heavily criticized by the Indian parliament for colluding with drug manufacturers. Chinese authorities do not allow proper access to inspectors from overseas, resulting in audit reports indicating that more than a third of Chinese ingredients come from unknown sources.

Many African countries do not have the expertise or money to monitor properly the quality of drugs in their own markets and the WHO does not have the budget or ability to monitor the drugs it has approved once they have made it onto the market.

International pressure therefore must be placed on Beijing and New Delhi to put their regulatory houses in order. Part of this pressure should come from international donors, who pay for many of these Chinese and Indian drugs on behalf of the poor in Africa. Donors should expose and combat the double standard of companies exploiting weak oversight to sell poor-quality products to lower-income markets. In the face of such a threat to public health, inaction is not an option.

Bate is a resident scholar at the American Enterprise Institute and the author of Phake: The Deadly World of Falsified and Substandard Medicines.

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Roger
Bate
  • Roger Bate is an economist who researches international health policy, with a particular focus on tropical disease and substandard and counterfeit medicines. He also writes on general development policy in Asia and Africa. He writes regularly for AEI's Health Policy Outlook.
  • Phone: 202-828-6029
    Email: rbate@aei.org
  • Assistant Info

    Name: Katherine Earle
    Phone: (202) 862-5872
    Email: katherine.earle@aei.org

What's new on AEI

image The money in banking: Comparing salaries of bank and bank regulatory employees
image What Obama should say about China in Japan
image A key to college success: Involved dads
image China takes the fight to space
AEI on Facebook
Events Calendar
  • 21
    MON
  • 22
    TUE
  • 23
    WED
  • 24
    THU
  • 25
    FRI
Wednesday, April 23, 2014 | 12:00 p.m. – 1:30 p.m.
Graduation day: How dads’ involvement impacts higher education success

Join a diverse group of panelists — including sociologists, education experts, and students — for a discussion of how public policy and culture can help families lay a firmer foundation for their children’s educational success, and of how the effects of paternal involvement vary by socioeconomic background.

Event Registration is Closed
Thursday, April 24, 2014 | 12:00 p.m. – 1:30 p.m.
Getting it right: A better strategy to defeat al Qaeda

This event will coincide with the release of a new report by AEI’s Mary Habeck, which analyzes why current national security policy is failing to stop the advancement of al Qaeda and its affiliates and what the US can do to develop a successful strategy to defeat this enemy.

Friday, April 25, 2014 | 9:15 a.m. – 1:15 p.m.
Obamacare’s rocky start and uncertain future

During this event, experts with many different views on the ACA will offer their predictions for the future.   

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.